Three potential paths - subpart H and others beyond that in a dialogue with FDA. Compelling data. FDA may find a way to work so that patients will have near term access to the drug that need it.
Another thing that he said that the path didn't necessarily include another trial.
He said "compelling" data???? Has to be more successes than what we knew in March.